Mojica Maria F, Ouellette Christopher P, Leber Amy, Becknell M Brian, Ardura Monica I, Perez Federico, Shimamura Masako, Bonomo Robert A, Aitken Samuel L, Shelburne Samuel A
Research Service, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA Department of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Department of Pediatrics, Division of Pediatric Infectious Diseases, Nationwide Children's Hospital and The Ohio State University, Columbus, Ohio, USA.
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5130-4. doi: 10.1128/AAC.00264-16. Print 2016 Sep.
Stenotrophomonas maltophilia is an emerging multidrug-resistant (MDR) opportunistic pathogen for which new antibiotic options are urgently needed. We report our clinical experience treating a 19-year-old renal transplant recipient who developed prolonged bacteremia due to metallo-β-lactamase-producing S. maltophilia refractory to conventional treatment. The infection recurred despite a prolonged course of colistimethate sodium (colistin) but resolved with the use of a novel drug combination with clinical efficacy against the patient's S. maltophilia isolate.
嗜麦芽窄食单胞菌是一种新出现的多重耐药（MDR）机会致病菌，迫切需要新的抗生素治疗选择。我们报告了我们治疗一名19岁肾移植受者的临床经验，该患者因产金属β-内酰胺酶的嗜麦芽窄食单胞菌导致长时间菌血症，对传统治疗无效。尽管使用了延长疗程的多粘菌素甲磺酸钠（多粘菌素），感染仍复发，但使用一种对患者的嗜麦芽窄食单胞菌分离株具有临床疗效的新型药物组合后感染得到解决。
